STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: We show that nilotinib-resistant CML cells undergo STAT3-dependent survival, apoptosis persistence, transcriptional and translational overexpression, and metabolic alterations; whereas, they could be re-sensitized to nilotinib through siRNA-mediated STAT3 targeting.